This article**: The people**.
People** 11th ed. on 31/01/2024).
Shanghai, January 30 (Reporter Jiang Hongbing) The Eye and Otolaryngology Hospital affiliated to Fudan University has led a major breakthrough in the hereditary deafness gene, and the world's first use of the developed gene ** drug to restore the hearing and speech of patients with hereditary deafness. On January 25, the clinical research results were published in The Lancet in the form of a long article, which showed the huge potential of genes for hereditary deafness, which will help promote the development and clinical application of deafness gene drugs.
It is understood that there are as many as 26 million congenital deafness patients worldwide. 60% of deafness in newborns is related to genetic factors, i.e., genetic defects, which severely hinder children's speech, cognitive and intellectual development.
In October 2022, the study entered clinical trials and implemented the inner ear gene** for the world's first case of hereditary deafness. Since then, the study has included multiple patients who received the gene**. At present, the maximum follow-up time is more than 1 year, and the child can have daily conversations. This is the world's first deafness gene** to be cured, and it is also one of the most systematic clinical trials in this field, with the largest number of cases and the longest follow-up time.